Kai Li is currently executive director in global strategic marketing at Incyte. Kai is accountable for market development and product strategy for Pemazyre TM and Itacitinib in oncology and hematology. Most recently, as the global marketing leader, Kai managed a marketing team to launch Pemazyre TM globally. Pemazyre TM first-year revenue exceeded analyst forecast by 150% in 2020. Kai also serves as the chairs of global commercialization team for both Pemazyre TM and Itacitinib. From 2016-2018, Kai led global product strategy for targeted therapy portfolio including six oncology assets ranging from phase 1 to pivotal trials.

​

From 2012-2016, Kai was the brand director in US sales and marketing at Johnson & Johnson and was accountable for leading US marketing strategy development and implementation of Zytiga ® in prostate cancer. Kai held P&L responsibilities for Zytiga ® and delivered over $1 billion in sales in both 2014 and 2015. From 2005 to 2012, Kai held leadership roles in strategic marketing at J&J and led the commercial development of several oncology drugs including global launch preparation for Zytiga ® . He was also instrumental in leading the acquisition of Cougar Biotech by J&J in 2009.

​

Prior to J&J, Kai worked as a business development manager in Biotechnology Division of Dow Chemical. Kai also served as senior scientist at Dow, where he was in charge of an R&D unit and generated multiple patents.

​

Kai received an MBA from The Wharton School, and earned a Ph.D. in Organic Chemistry and Biochemistry from Michigan State University and a BS in Chemistry from
Peking University